The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates

Several COVID-19 platforms have been licensed across the world thus far, but vaccine platform research that can lead to effective antigen delivery is still ongoing. Here, we constructed AdCLD-CoV19 that could modulate humoral immunity by harboring SARS-CoV-2 antigens onto a chimeric adenovirus 5/35...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Seung-Phil, Shin, Kwang-Soo, Lee, Jeong-Mi, Jung, In-Kyung, Koo, Jimo, Lee, Seung-Woo, Park, Seowoo, Shin, Jieun, Park, Myunghwan, Park, Bongju, Oh, Hanseul, Koo, Bon-Sang, Hong, Jungjoo, Ryu, Choong-Min, Kim, Jae-Ouk, Oh, Taegwon, Kang, Chang-Yuil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147121/
https://www.ncbi.nlm.nih.gov/pubmed/35632468
http://dx.doi.org/10.3390/vaccines10050712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147121/
https://www.ncbi.nlm.nih.gov/pubmed/35632468
http://dx.doi.org/10.3390/vaccines10050712

Ejemplares similares